Anebulo Pharmaceuticals Stock Performance
| ANEB Stock | USD 1.15 0.03 2.54% |
The firm shows a Beta (market volatility) of 0.35, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Anebulo Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Anebulo Pharmaceuticals is expected to be smaller as well. At this point, Anebulo Pharmaceuticals has a negative expected return of -0.22%. Please make sure to confirm Anebulo Pharmaceuticals' treynor ratio, skewness, and the relationship between the jensen alpha and value at risk , to decide if Anebulo Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Anebulo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's technical and fundamental indicators remain somewhat strong which may send shares a bit higher in June 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Anebulo Pharmaceuticals GAAP EPS of -0.09 misses by 0.01 | 02/14/2025 |
2 | Anebulo Pharmaceuticals Enters Private Placement and Lock-Up Agreement, Receives Nasdaq Extension | 02/26/2025 |
3 | Acquisition by English Aron R. of 10101010 shares of Anebulo Pharmaceuticals at 0.99 subject to Rule 16b-3 | 03/21/2025 |
4 | Acquisition by Kupchyk Areta of 2647 shares of Anebulo Pharmaceuticals at 1.02 subject to Rule 16b-3 | 04/04/2025 |
5 | Acquisition by Calloway Nathaniel of 25000 shares of Anebulo Pharmaceuticals at 1.02 subject to Rule 16b-3 | 04/07/2025 |
| Begin Period Cash Flow | 11.2 M |
Anebulo Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 153.00 in Anebulo Pharmaceuticals on February 4, 2025 and sell it today you would lose (38.00) from holding Anebulo Pharmaceuticals or give up 24.84% of portfolio value over 90 days. Anebulo Pharmaceuticals is currently does not generate positive expected returns and assumes 6.9708% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than Anebulo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Anebulo Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Anebulo Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Anebulo Pharmaceuticals, and traders can use it to determine the average amount a Anebulo Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0317
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ANEB |
Estimated Market Risk
| 6.97 actual daily | 62 62% of assets are less volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Anebulo Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Anebulo Pharmaceuticals by adding Anebulo Pharmaceuticals to a well-diversified portfolio.
Anebulo Pharmaceuticals Fundamentals Growth
Anebulo Stock prices reflect investors' perceptions of the future prospects and financial health of Anebulo Pharmaceuticals, and Anebulo Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Anebulo Stock performance.
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | 32.25 M | ||||
| Shares Outstanding | 41.08 M | ||||
| Price To Book | 3.16 X | ||||
| EBITDA | (8.05 M) | ||||
| Net Income | (8.2 M) | ||||
| Cash And Equivalents | 14.55 M | ||||
| Cash Per Share | 0.62 X | ||||
| Total Debt | 260.58 K | ||||
| Current Ratio | 30.40 X | ||||
| Book Value Per Share | 0.36 X | ||||
| Cash Flow From Operations | (8.09 M) | ||||
| Earnings Per Share | (0.29) X | ||||
| Market Capitalization | 47.25 M | ||||
| Total Asset | 4.07 M | ||||
| Retained Earnings | (65.4 M) | ||||
| Working Capital | 3.25 M | ||||
About Anebulo Pharmaceuticals Performance
By analyzing Anebulo Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Anebulo Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Anebulo Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Anebulo Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.32) | (2.20) | |
| Return On Capital Employed | (2.51) | (2.38) | |
| Return On Assets | (2.32) | (2.20) | |
| Return On Equity | (2.47) | (2.35) |
Things to note about Anebulo Pharmaceuticals performance evaluation
Checking the ongoing alerts about Anebulo Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Anebulo Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Anebulo Pharmaceuticals generated a negative expected return over the last 90 days | |
| Anebulo Pharmaceuticals has high historical volatility and very poor performance | |
| Anebulo Pharmaceuticals may become a speculative penny stock | |
| Net Loss for the year was (8.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Anebulo Pharmaceuticals currently holds about 14.55 M in cash with (8.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62. | |
| Anebulo Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 41.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Calloway Nathaniel of 25000 shares of Anebulo Pharmaceuticals at 1.02 subject to Rule 16b-3 |
- Analyzing Anebulo Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Anebulo Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Anebulo Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Anebulo Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Anebulo Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Anebulo Pharmaceuticals' stock. These opinions can provide insight into Anebulo Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Anebulo Stock analysis
When running Anebulo Pharmaceuticals' price analysis, check to measure Anebulo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anebulo Pharmaceuticals is operating at the current time. Most of Anebulo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Anebulo Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anebulo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Anebulo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |